Holen Sie sich die Stockscreener-App
7.99
0.12%
-0.010
Schlusskurs vom Vortag:
$8.00
Offen:
$8.1
24-Stunden-Volumen:
1.11M
Relative Volume:
0.52
Marktkapitalisierung:
$1.38B
Einnahmen:
$25.55M
Nettoeinkommen (Verlust:
$-341.97M
KGV:
-2.8536
EPS:
-2.8
Netto-Cashflow:
$-304.44M
1W Leistung:
-2.32%
1M Leistung:
+5.41%
6M Leistung:
+109.71%
1J Leistung:
+65.42%
1-Tages-Spanne:
$7.92
$8.24
1-Wochen-Bereich:
$7.66
$8.66
52-Wochen-Spanne:
$1.775
$9.04
Relay Therapeutics Inc Stock (RLAY) Company Profile
Firmenname
Relay Therapeutics Inc
Sektor
Branche
Telefon
617-370-8837
Adresse
60 HAMPSHIRE STREET, CAMBRIDGE
Vergleichen Sie RLAY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
7.99 | 1.39B | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-04-17 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-09-10 | Fortgesetzt | Goldman | Buy |
| 2024-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-04-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Eingeleitet | Raymond James | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-09-30 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-02 | Eingeleitet | Stifel | Buy |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-07-21 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-11-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-10 | Eingeleitet | Cowen | Outperform |
| 2020-08-10 | Eingeleitet | Goldman | Buy |
| 2020-08-10 | Eingeleitet | Guggenheim | Buy |
| 2020-08-10 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
Why Relay Therapeutics Inc. stock could outperform in 2025July 2025 Short Interest & Long Hold Capital Preservation Plans - ulpravda.ru
Will Relay Therapeutics Inc. stock deliver shareholder valueTrade Entry Report & Technical Analysis for Trade Confirmation - ulpravda.ru
Is Relay Therapeutics Inc. stock a contrarian buyJuly 2025 Fed Impact & Verified Chart Pattern Signals - ulpravda.ru
Will Relay Therapeutics Inc. stock benefit from sector rotationQuarterly Risk Review & Low Risk Profit Maximizing Plans - ulpravda.ru
Will Relay Therapeutics Inc. stock split attract more investors2025 Technical Overview & Consistent Income Trade Recommendations - ulpravda.ru
How strong is Relay Therapeutics Inc. stock balance sheetWeekly Volume Report & Daily Oversold Bounce Ideas - ulpravda.ru
Why Relay Therapeutics Inc. stock could benefit from AI revolutionWall Street Watch & Weekly High Conviction Trade Ideas - ulpravda.ru
How Relay Therapeutics Inc. stock performs in rate cut cyclesRisk Management & Low Drawdown Trading Techniques - ulpravda.ru
CEO Change: Will Relay Therapeutics Inc. stock pay special dividendsEarnings Recap Summary & Daily Entry Point Trade Alerts - ulpravda.ru
Is Relay Therapeutics Inc. stock a buy before product launchesEnergy Sector Updates & Free Professional Investment Consultations - ulpravda.ru
User | guymondailyherald.comRelay Therapeutics, Inc.Common Stock (Nasdaq:RLAY) Stock Quote - FinancialContent
Relay Therapeutics Q3 2025 Earnings Preview - MSN
What makes Relay Therapeutics Inc. stock attractive to growth funds2026 world cup usa national team round of 32 goalkeepers low block defense knockout prediction guide - ulpravda.ru
Relay Therapeutics CEO Sanjiv Patel sells $818,399 in stock - MSN
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Unpacking the 72.58% Potential Upside in Precision Medicine - DirectorsTalk Interviews
Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week - MSN
Aug Action: What makes Relay Therapeutics Inc. stock attractive to growth fundsPortfolio Value Report & Weekly High Conviction Trade Ideas - moha.gov.vn
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Take Profit: Can Relay Therapeutics Inc. stock hit record highs again2025 Valuation Update & Precise Trade Entry Recommendations - moha.gov.vn
Will Relay Therapeutics Inc. stock gain from strong economyFibonacci Retracement Levels & Analyze Your Portfolio Risk in Seconds - bollywoodhelpline.com
Relay Therapeutics (NASDAQ:RLAY) Shares Up 4.9%Here's What Happened - MarketBeat
Congress Asset Management Co. Has $2.13 Million Stock Holdings in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics signals slowdown to recharge after busy year - Traders Union
Will Relay Therapeutics Inc stock pay special dividendsMarket Sentiment Report & Verified Technical Signals - moha.gov.vn
Zovegalisib’s Consistent Efficacy Across Tough Subgroups Could Be A Game Changer For Relay (RLAY) - simplywall.st
What sentiment indicators say about Relay Therapeutics Inc. stockQuarterly Market Summary & High Win Rate Trade Alerts - Улправда
Can Relay Therapeutics Inc. stock hit analyst price targets2025 Sector Review & AI Enhanced Trading Alerts - Улправда
Is Relay Therapeutics Inc. stock attractive for passive investors2025 Biggest Moves & Risk Managed Investment Entry Signals - Улправда
Can Relay Therapeutics Inc. stock resist market sell offsPortfolio Return Report & Low Risk High Reward Ideas - DonanımHaber
Can Relay Therapeutics Inc. stock hit record highs againTake Profit & High Conviction Buy Zone Picks - DonanımHaber
How Relay Therapeutics Inc. stock reacts to oil pricesTrade Performance Summary & Daily Profit Focused Stock Screening - Улправда
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares - AOL.com
Alert from Equity-Insider.com was published in error and has been withdrawn - marketscreener.com
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards - GlobeNewswire
Relay Therapeutics (NASDAQ:RLAY) Trading Up 4.7%Here's What Happened - MarketBeat
Relay Therapeutics (RLAY): Revisiting Valuation After a Sharp Rebound in 2024 - Yahoo Finance
Will Broad Zovegalisib Breast Cancer Data Reshape Relay Therapeutics' (RLAY) Targeted Oncology Narrative? - Yahoo Finance
Relay Therapeutics (NASDAQ:RLAY) Sets New 1-Year HighStill a Buy? - MarketBeat
Bellevue Group AG Boosts Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics stock hits 52-week high at 8.62 USD By Investing.com - Investing.com Australia
Wells Fargo Upgrades Relay Therapeutics (RLAY) - Nasdaq
Relay Therapeutics Reports 'Robust Activity' For Precision Breast Cancer Drug - Sahm
Why Is Relay Therapeutics Stock Gaining Friday?Relay Therapeutics (NASDAQ:RLAY) - Benzinga
RLAY Stock Receives Analyst Upgrade and Price Target Boost | RLA - GuruFocus
Relay Therapeutics stock hits 52-week high at 8.62 USD - Investing.com India
Relay Therapeutics Reports 'Robust Activity' in Study of Zovegalisib to Treat Breast Cancer - marketscreener.com
Relay Therapeutics (RLAY) Shares New Data from Zovegalisib Study - GuruFocus
Relay Therapeutics unveils efficacy subset analysis for zovegalisib at SABCS25 - Traders Union
Relay Therapeutics Reports Positive Efficacy Data for Zovegalisib in Metastatic Breast Cancer at SABCS 2025 - Quiver Quantitative
Finanzdaten der Relay Therapeutics Inc-Aktie (RLAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Relay Therapeutics Inc-Aktie (RLAY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Patel Sanjiv | President and CEO |
Nov 03 '25 |
Sale |
7.00 |
62,073 |
434,511 |
703,215 |
| Rahmer Peter | See remarks |
Oct 29 '25 |
Sale |
7.50 |
21,394 |
160,455 |
337,469 |
| Rahmer Peter | See remarks |
Oct 28 '25 |
Sale |
7.29 |
19,135 |
139,494 |
358,863 |
| Catinazzo Thomas | Chief Financial Officer |
Oct 28 '25 |
Sale |
7.29 |
21,664 |
157,931 |
313,631 |
| Bergstrom Donald A | President, R&D |
Oct 28 '25 |
Sale |
7.29 |
30,897 |
225,239 |
521,823 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):